AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee

Phase 3

Completed

• Conditions: Knee Osteoarthritis; Knee Pain Chronic; Osteoarthritis, Knee; Knee Arthritis
• Interventions: Drug: 4 mL Injection of Placebo; Biological: 4 mL injection of Ampion

• Registration Number: NCT03182686
• Lead Sponsor: Ampio Pharmaceuticals. Inc.

Brief Summary

This is a phase 3 randomized study to confirm the efficacy of an intra-articular injection of Ampion™ in adults with pain due to severe osteoarthritis of the knee.

Detailed Description

A Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee

There will be a 7-day screening period for each subject followed by a 12-week participation period.

The primary trial objective is to evaluate the clinical efficacy of Ampion using the Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) (using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) 3.1 Index and Patient's Global Assessment as assessments).

The secondary trial objectives are to evaluate the safety of a single intra-articular injection (4 mL) of Ampion.

Study Timeline

• Study First Submitted: 2017-06-06
• Study First Submitted QC: 2017-06-08
• Study First Posted: 2017-06-09
• Study Start: 2017-06-19
• Primary Completion: 2017-12-07
• Study Completion: 2017-12-07
• Disposition First Submitted: 2019-06-17
• Disposition First Submitted QC: 2019-06-18
• Disposition First Posted: 2019-06-20
• Results First Submitted: 2022-07-12
• Results First Submitted QC: 2022-07-12
• Status Verified: 2022-08
• Results First Posted: 2022-08-08
• Last Update Submitted: 2022-08-08
• Last Update Posted: 2022-08-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 168

Inclusion Criteria

• Able to provide written informed consent to participate in the study;
• Willing and able to comply with all study requirements and instructions of the site study staff;
• Must be ambulatory;
• Study knee must have a clinical diagnosis of osteoarthritis (OA) supported by radiological evidence (Kellgren Lawrence Grade IV) which is assessed locally (x-rays within the past 6 months of screening are acceptable);
• Moderate to moderately-severe OA pain in the study knee (rating of at least 1.5 on the WOMAC A, 5-point Likert Pain Subscale);
• Moderate to moderately-severe OA function in the study knee (rating of at least 1.5 on the WOMAC C, 5-point Likert Function Subscale);
• WOMAC A, 5-point Likert pain subscale <1.5 in the contralateral knee;
• Ability to discontinue non-steroidal anti-inflammatory drug (NSAID) use at Screening visit and/or 72 hours prior to the Baseline visit and for the duration of the clinical study (low-dose aspirin (81 mg) is allowed during the study);
• No analgesia (including acetaminophen) taken 24 hours prior to an efficacy measure;
• No known clinically significant liver abnormality (e.g. cirrhosis, transplant, etc.).

Exclusion Criteria

• As a result of medical review and screening investigation, the Principal Investigator considers the subject unfit for the study

• A history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion)

• A history of allergic reactions to excipients in 5% human albumin (N-acetyltryptophan, sodium caprylate)

• Presence of tense effusions

• Inflammatory or crystal arthropathies, acute fractures, history of aseptic necrosis or joint replacement in the affected knee, as assessed locally by the Principal Investigator

• Isolated patella femoral syndrome, also known as chondromalacia

• Any other disease or condition interfering with the free use and evaluation of the study knee for the duration of the trial (e.g. cancer, congenital defects, spine osteoarthritis)

• Major injury to the study knee within the 12 months prior to screening

• Severe hip osteoarthritis ipsilateral to the study knee

• Any pain that could interfere with the assessment of study knee pain (e.g. pain in any other part of the lower extremities, pain radiating to the knee)

• Any pharmacological or non-pharmacological treatment targeting OA started or changed during the 4 weeks prior to randomization or likely to be changed during the duration of the study

• Pregnancy or planning to become pregnant during the study

• Use of the following medications:

  1. No intra-articular (IA) injected medications in the study knee during the study (or 12 weeks prior to Baseline).
  2. No analgesics containing opioids.
  3. NSAIDs are not permitted during the study; acetaminophen is available as a rescue medication during the study from the provided supply.
  4. No topical treatment on the study knee during the study
  5. No significant anticoagulant therapy (e.g. Heparin or Lovenox) during the study (treatment such as low-dose Aspirin (81 mg) and Plavix are allowed)
  6. No systemic treatments that may interfere with safety or efficacy assessments during the study
  7. No immunosuppressants
  8. No use of systemic or intra-articular corticosteroids

• No human albumin treatment in the 3 months before randomization or throughout the duration of the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo 4 mL dose	4 mL Injection of Placebo	4 mL injection of Placebo
AMPION™ 4 mL dose	4 mL injection of Ampion	4 mL injection of Ampion

Primary Outcome Measures

Name	Time	Method
Number of Participants Classified as Responders	Determined from Baseline to 12 Weeks	Using the Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) criteria of WOMAC A Pain subscore, WOMAC C Function subscore, and PGA as composite endpoints. A patient in this study will be considered a responder for the purpose of efficacy analysis if the following criteria are met: (1) demonstration of ≥ 50% improvement AND a 1.0-unit change in pain OR 1.0-unit change in function OR; If the patient does not meet this criterion, then the patient must demonstrate at least 2 of the following: * Improvement in pain (WOMAC A) ≥20% and a 0.5 point absolute change in pain from Baseline on the 5-point Likert scale; * Improvement in function (WOMAC C) ≥20% and a 0.5 point absolute change in function from Baseline on the 5-point Likert scale; * Improvement in patient global assessment (PGA) ≥20% and a 0.5 point absolute change in function from Baseline on the 5-point Likert scale

Trial Locations

Locations (13)

St. Joseph Heritage; 🇺🇸 Fullerton, California, United States

Westlake Medical Research; 🇺🇸 Thousand Oaks, California, United States

Central Research Associates, Inc.; 🇺🇸 Birmingham, Alabama, United States

CORE Orthopaedic Medical Center; 🇺🇸 Encinitas, California, United States

Artemis Institute for Clinical Research; 🇺🇸 San Diego, California, United States

Arthritis Treatment Center; 🇺🇸 Frederick, Maryland, United States

Tekton Research; 🇺🇸 Austin, Texas, United States

Drug Studies America; 🇺🇸 Marietta, Georgia, United States

Healthcare Research Netword; 🇺🇸 Blue Island, Illinois, United States

Healthcare Network Research; 🇺🇸 Hazelwood, Missouri, United States

Heartland Research Associates; 🇺🇸 Wichita, Kansas, United States

Coastal Carolina Center at Lowcountry Orthopaedics; 🇺🇸 North Charleston, South Carolina, United States

Northwest Clinical Research Center; 🇺🇸 Bellevue, Washington, United States